Biocryst Pharmaceuticals Inc revenue
Biocryst Pharmaceuticals Inc's revenue was $875m in fiscal 2025, up 94.1% on the year before. Since fiscal 2009 ($74.6m) it has grown at a compound 16.6% a year. Over the last twelve months it was $941m.
Revenue history
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 75 | 62 | 20 | 26 | 17 | 14 | 48 | 26 | 25 | 21 | 49 | 18 | 157 | 271 | 331 | 451 | 875 | 941 |
| Growth on the year before | — | −16.4% | −68.5% | +33.9% | −34.1% | −21.5% | +254.6% | −45.4% | −4.4% | −18.0% | +136.5% | −63.5% | +782.4% | +72.3% | +22.4% | +36.0% | +94.1% | — |
| Gross profit | 70 | 62 | — | — | — | — | — | 24 | 24 | — | 45 | 16 | 150 | 264 | 327 | 438 | 856 | 920 |
| Gross margin | 93.9% | 99.9% | — | — | — | — | — | 91.3% | 95.5% | — | 92.4% | 91.3% | 95.4% | 97.6% | 98.6% | 97.3% | 97.8% | 97.8% |
Where the revenue comes from
| Line of business | Revenue | YoY |
|---|---|---|
| Products | $623M | ▲ 40.8% |
| ORLADEYO | $602M | ▲ 37.5% |
| License and Other Revenues | $252M | ▲ 3028.9% |
| Licenses | $244M | — |
| Other Income From Contract With Customer | $29M | ▲ 122.3% |
| Collaborative and Other Research and Development | $7.7M | ▼ 4.2% |
These categories overlap or exclude eliminations, so shares aren't shown.
From Biocryst Pharmaceuticals Inc's 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Biocryst Pharmaceuticals Inc | $941m | 68.7% | 45.3% |
| Bridgebio Pharma, Inc. | $946m | 167.3% | 364.6% |
| Kiniksa Pharmaceuticals International, plc | $946m | 58.2% | 56.1% |
| Ionis Pharmaceuticals Inc | $874m | -7.4% | 11.5% |
| Legend Biotech Corp | $1.03bn | 64.0% | — |
| Ascendis Pharma A/s | $814m | 106.9% | — |
Compare with peers
- Bridgebio Pharma, Inc. revenue
- Kiniksa Pharmaceuticals International, plc revenue
- Ionis Pharmaceuticals Inc revenue
- Legend Biotech Corp revenue
- Ascendis Pharma A/s revenue
Head to head: BBIO vs BCRXBCRX vs KNSABCRX vs IONSBCRX vs LEGN
More: Biotechnology stocks compared, Health Care sector, rankings of US companies